Currently, IL-15 is being tested in combination with other mAbs directed against tumor-associated antigens, with Alemtuzumab (anti-CD52) in adult patients with T-cell leukemia (NCT02689453) and Obinutuzumab (anti-CD20) in patients with chronic lymphocyte leukemia (NCT03759184). This evidence concerns the gene CD52 and T-cell leukemia.